Innovative Industrial Properties: Undervalued Amid Cannabis Rescheduling Milestone
The cannabis rescheduling milestone marks a pivotal change in federal law, impacting medical cannabis research and clinical practice. This shift to Schedule III could accelerate pharmaceutical development and alter regulatory frameworks. Understanding…
Pot Inc. Awaits DOJ Marijuana Reclassification Decision Amid Delays
The DOJ marijuana reclassification delay continues to affect medical cannabis research and clinical practice. This postponement hinders progress toward Schedule III status, which could improve research opportunities. Understanding this delay is crucial…
In the Mix: 10 More Articles — March 19, 2026
This article reviews cannabis regulatory enforcement challenges 2026 impacting legal cannabis markets and clinical practice. It highlights key compliance issues and regulatory updates. Understanding these challenges is essential for clinicians and…
Federal CBD Health Insurance Plan Allows THC Above Hemp Limit
Federal CBD insurance coverage now permits products with up to 3mg THC per dose, marking a significant policy shift. This change impacts dosing and safety considerations for clinicians. Understanding this federal cbd insurance coverage is crucial for…
Lowcountry Hemp Sellers Challenge DEA Enforcement Actions
Hemp-derived THC enforcement by the DEA has led to raids on Lowcountry hemp retailers, prompting legal challenges. These actions highlight federal uncertainty around hemp products. The lawsuit aims to clarify enforcement and protect hemp businesses.
Congressional Researchers Provide Update on Marijuana Rescheduling and Hemp Policy
Marijuana rescheduling federal research is under active congressional review, affecting clinical practice and research access. Current federal Schedule I status limits federally funded cannabis studies. Changes in rescheduling could enhance…
Feds Maintain Marijuana Testing Despite Cannabis Reclassification
Federal workplace drug testing policies continue to screen for marijuana metabolites despite cannabis reclassification. This creates challenges for patients using cannabis medicinally in safety-sensitive jobs. Clinicians should counsel patients on the…
FDA Submits New Cannabis Products Enforcement Policy For White House Review
The FDA cannabis enforcement policy marks a key regulatory step for the evolving cannabis marketplace. This policy aims to standardize product labeling and safety documentation. Clinicians should monitor this policy for clearer guidance on cannabis…
Pa. Senate Amends Cannabis Bill with Stricter Pennsylvania Hemp Standards
Pennsylvania hemp standards have been updated to align with stricter federal regulations, enhancing cannabis product safety. These changes reduce contamination risks and improve product consistency for medical cannabis users. Clinicians can now counsel…
With Marijuana Rescheduling Still Pending, Federal Workplace Drug Testing Rules Aren’t Changing
Federal workplace drug testing policies marijuana remain unchanged despite ongoing cannabis rescheduling efforts. This creates challenges for clinicians counseling patients on employment risks. Understanding these policies is crucial for navigating the…